Highlights from Day 2 of the ESC 2021 congress – MASTER DAPT

Presented by Dr. Marco Valgimigli, the MASTER DAPT trial assessed whether 1 month of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), with a…

View More Highlights from Day 2 of the ESC 2021 congress – MASTER DAPT
BMJ Visual Summary

FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway

By Elisabeth Mahase Taken Directly from the BMJ doi: https://doi.org/10.1136/bmj.n1898 Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent…

View More FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway
ECG

Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure

By Syed Ghias Take Home Messages Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a novel class of oral hypoglycaemic medications which have been shown to be effective…

View More Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure
Procedure

Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44,000 patients

Dr Amit Bhan examines a study on Novel Oral Anticoagulants recently published in the European Heart Journal.

View More Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44,000 patients